ProhostBiotech.Com

Home

News and Comments

Subscribe Now

About Us

Most Discussed Stocks

ALNYLAM PHARMACEUTICALS, ALNY

AMGEN, AMGN

BIOGEN IDEC, BIIB

CYTOKINETICS, CYTK

DENDREON,DNDN

DYAX, DYAX

ELAN, ELN

GENENTECH,DNA

GILEAD SCIENCES,GILD

ONYX PHARMACEUTICALS,ONXX

OSIRIS THERAPEUTICS, OSIR

REGENERON,RGEN

SAVIENT PHARMACEUTICALS, SAVIENT (SVNT)

SEQUENOM,SQNM

SANGAMO BIOSCIENCES, SGMO

EXELIXIS, EXEL

Biotech News and Comments

ISIS (ISIS): Lou Gehrigs Disease Antisense Drug Has Reached Clinical Trials

Isis initiated a Phase 1 study of its antisense drug ISIS-SOD1Rx in patients with an inherited, aggressive form of Lou Gehrig's disease also known as familial amyotrophic lateral sclerosis. (ALS). As ISIS-SOD1Rx selectively inhibits the production of SOD1, it is expected to benefit the cases of familial ALS that are related to mutant forms of superoxide dismutase, or SOD1, which constitutes approximately 20% of ALS patients suffering from familial ALS.

	ON SEQUENOM (SQNM)	03/02/2010
	This firm is speeding towards erasing two thirds of investors’ skepticism towards its technological capability. In the past month Sequenom launched SensiGene™ Fetal RHD Genotyping ....

	Time To Appreciate ISIS PHARMACEUTICALS (ISIP....	03/02/2010
	ISIS was subjected to a sell-off following the announcement of decidedly positive phase 3 results of the firm’s drug Mipomersen for familial hypercholesterolemia (FH). Some interpr....

	OSI (OSIP): Congratulation Prohost Subscriber....	03/01/2010
	It was easy to predict and Prohost did not miss. Prohost did not predict the name of the buyer, but has predicted a take over and kept reminding its shareholders about this prophec....

	CADENCE (CADX): The FDA Complete Response is ....	02/16/2010
	CADENCE PHARMACEUTICALS (CADX): The FDA decision to deny approval of Cadence’s drug Ofirmev™ (IV acetaminophen) was positive rather than negative news. The contents of the FDA Comp....

	XOMA: Past, Present and Future.	02/09/2010
	The firm has encouraging news today. But recently the firm’s stock plummeted for reasons not related to the firm’s technological capabilities, but to a mixture of inherited consequ....

	WE ARE BACK FROM HALF REST, GILEAD, TYSABRI ....	01/27/2010
	January is almost gone, and February is knocking on the door. Be ready to hear good news. We have plenty. For subscribers Only.

	SUNESIS PHARMACEUTICALS (SNSS): RESULTS CANNO....	01/02/2010
	At the 51st American Society Hematology (ASH) Annual Meeting in New Orleans, LA. Sunesis presented positive data from two Phase 2 clinical trials of its drug Voreloxin drug for acu....